Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$ALT Q4 '24 Earnings Results & Recap
Altimmune's Q4'24 results showed EPS of -$0.33 (matching expectations), with no reported revenue as expected. The upcoming Phase 2b readout for pamidutide in NASH and the initiation of Phase 2 trials for two additional indications are key catalysts for 2025, with potential for significant revenue generation if successful.8
15
